Ken Griffin Rx Sight, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Rx Sight, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 167,000 shares of RXST stock, worth $2.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

167,000

Previous 89,000 87.64%

Holding current value

$2.72 Million

Previous $3.06 Million 37.82%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$24.37 - $35.84 $18.6 Million - $27.4 Million	-763,946 Reduced 76.84%	230,221 $5.81 Million
Q4 2024 Feb 14, 2025	BUY	$33.66 - $54.73 $26.3 Million - $42.8 Million	782,424 Added 369.52%	994,167 $34.2 Million
Q3 2024 Nov 14, 2024	BUY	$40.78 - $57.04 $3.44 Million - $4.81 Million	84,253 Added 66.09%	211,743 $10.5 Million
Q2 2024 Aug 14, 2024	SELL	$50.42 - $64.29 $191,041 - $243,594	-3,789 Reduced 2.89%	127,490 $7.67 Million
Q1 2024 May 15, 2024	BUY	$35.51 - $57.92 $815,025 - $1.33 Million	22,952 Added 21.19%	131,279 $6.77 Million
Q4 2023 Feb 14, 2024	BUY	$20.91 - $40.9 $2.21 Million - $4.32 Million	105,526 Added 3767.44%	108,327 $4.37 Million
Q3 2023 Nov 14, 2023	SELL	$27.05 - $33.37 $6.91 Million - $8.53 Million	-255,473 Reduced 98.92%	2,801 $78,000
Q2 2023 Aug 14, 2023	BUY	$16.37 - $28.9 $3.46 Million - $6.1 Million	211,154 Added 448.12%	258,274 $7.44 Million
Q1 2023 May 15, 2023	BUY	$12.58 - $16.68 $486,632 - $645,232	38,683 Added 458.49%	47,120 $785,000
Q4 2022 Feb 14, 2023	SELL	$9.93 - $14.2 $153,507 - $219,517	-15,459 Reduced 64.69%	8,437 $106,000
Q3 2022 Nov 14, 2022	SELL	$11.19 - $15.85 $68,169 - $96,558	-6,092 Reduced 20.31%	23,896 $287,000

Others Institutions Holding RXST

# of Institutions

202

Shares Held

34.5M

Call Options Held

269K

Put Options Held

8.5K

View Full List

About RxSight, Inc.

Ticker RXST
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 27,638,900
Market Cap $450M
Description
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. T...

More about RXST

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account